Denosumab for the Prevention of Osteoporotic Fractures in Postmenopausal Women

Health Technology Assessment - United Kingdom
doi 10.3310/hta15suppl1/06
Full Text
Abstract

Available in full text

Date
Authors
Publisher

National Institute for Health Research

Related search

Once-Yearly Zoledronic Acid in the Prevention of Osteoporotic Bone Fractures in Postmenopausal Women

Clinical Interventions in Aging
MedicineGerontologyGeriatrics
2008English

Parenteral and Oral Pharmacotherapy in Prevention of Osteoporotic Fractures in Postmenopausal Osteoporosis

Przeglad Menopauzalny
GynecologyEndocrinologyMetabolismObstetricsDiabetes
2013English

Pms46 - Cost-Effectiveness of Primary Prevention for Osteoporotic Hip Fractures in Elderly Women

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Prevention of Postmenopausal Osteoporotic Fractures: Results of the Health Technology Assessment of a New Antiosteoporotic Drug

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2014English

Prevention of Osteoporosis-Related Fractures Among Postmenopausal Women and Older Men

CMAJ
Medicine
2009English

Pharmacotherapy of Bone Loss in Postmenopausal Women: Focus on Denosumab

Clinical Medicine. Therapeutics
2009English

Serum Osteocalcin Levels in Postmenopausal Osteoporotic Women Receiving Alendronate

Rheumatology Research
2018English

Effect of Denosumab on Trabecular Bone Score in Postmenopausal Women With Osteoporosis

Osteoporosis International
MedicineEndocrinologyMetabolismDiabetes
2017English

A Review of the Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis

Therapeutic Advances in Musculoskeletal Disease
RheumatologyOrthopedicsSports Medicine
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy